

Regimen Reference Order – GAST – OFF

ARIA: GAST – [OFF]

Planned Course: Every 42 days (Days 1, 8, 15 and 22) until disease progression or unacceptable toxicity

Indication for Use: Pancreatic Cancer Metastatic

CVAD: Required (Ambulatory Pump)

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST - OFF

Establish primary solution 500 mL of: D5W

Drug	Dose	CCMB Administration Guideline
Days 1 and 15		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
fluorouracil	2000 mg/m ²	IV in D5W continuously over 24 hours by ambulatory infusion device
Days 8 and 22		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
oxaliplatin	85 mg/m ²	IV in D5W 500 mL over 2 hours
fluorouracil	2000 mg/m ²	IV in D5W continuously over 24 hours by ambulatory infusion device

All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Day 8, 15 and 22

- CBC as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
dexamethasone	8 mg	Orally once daily on Days 9 and 10 and on Days 23 and 24
prochlorperazine	10 mg	Orally every 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Ensure patient has received a home chemotherapy spill kit and instructions for use
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- oxaliplatin causes cold intolerance and laryngopharyngeal dysesthesia
 - no ice chips or cold drinks
- oxaliplatin may cause progressive, irreversible neuropathy
 - dose modification may be required